Futibatinib is a special inhibitor that zeroes in on the FGFR pathway. It’s a big deal for cholangiocarcinoma patients who have FGFR2 fusions. The drug keeps the FGFR signaling from going haywire, which usually gets messed up in cancer cells.
Futibatinib comes in 4 mg tablets. The usual dose is 20 mg, taken just once every day. The tablets are packed in bottles, with each bottle holding 28 of ’em.
The main ingredient in Futibatinib is made to be swallowed, which helps make sure it gets absorbed and works right.
Reviews
There are no reviews yet.